Background Findings from the randomised phase 3 NeoALTTO trial in women with HER2-positive early breast cancer showed that the combination of lapatinib and trastuzumab signifi cantly improved rates of pathological complete response compared with either drug alone. Here, we report data for the prespecifi ed secondary endpoints of eventfree and overall survival, and assess the association between these outcomes and pathological complete response.
Introduction
Overexpression or amplifi cation of HER2 occurs in roughly 15% of breast cancers, and is associated with poor prognosis. 1 Anti-HER2 drugs such as the monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib are widely used for the treatment of HER2-positive breast cancer; trastuzumab is approved for use in the metastatic and adjuvant settings, whereas lapatinib is approved in the metastatic setting only. [2] [3] [4] [5] [6] Previously, we reported fi ndings from the phase 3, randomised NeoALTTO study, 7 which showed that dual anti-HER2 inhibition with lapatinib and trastuzumab combined with weekly paclitaxel signifi cantly increased the proportion of patients achieving pathological complete response in the combination group compared with trastuzumab ( 8 Here, we report the prespecifi ed secondary outcomes of event-free and overall survival from NeoALTTO, and the association between achievement of loco regional pathological complete response (ypT0/is ypN0) and survival outcomes.
Methods

Study design and participants
Study design and patient eligibility has been reported previously. 7 Briefl y, 455 women were randomly assigned between Jan 5, 2008 , and May 27, 2010 , to one of the three parallel treatment groups: oral lapatinib, intravenous trastuzumab, or lapatinib plus trastuzumab. Key eligibility criteria included histologically confi rmed HER2-positive early breast cancer, 9 tumour size greater than 2 cm, adequate hepatic, renal, cardiac, and bone marrow function at baseline, and left ventricular ejection fraction at baseline of 50% or more. HER2 status was assessed centrally (Vall D'Hebron Institute of Oncology, Barcelona, Spain) or locally (after central laboratory accreditation); hormonereceptor status was considered positive or negative as per local guidelines. Women with bilateral, infl ammatory, or metastatic breast cancer were not eligible. 7 The ethics committee and relevant health authorities at each participating institution approved the study protocol. All participating women gave written informed consent before study entry.
Randomisation and masking
As previously reported, 7 treatment allocation was by stratifi ed, permuted blocks randomisation. With a block size of six, patients were randomly assigned to the three treatments in a 2:2:2 ratio. There were four stratifi cation factors: hormone-receptor status (oestrogen-receptor or progesterone-receptor positive, or both, vs both oestrogenreceptor and progesterone-receptor negative); clinical involvement of axillary lymph nodes (N0-1 vs ≥N2); clinical tumour size (T2 [2-5 cm diameter]) vs ≥T3 [>5 cm diameter]); and suitability for breast-conserving surgery (yes vs no). The trial was open label, although investigators assessing outcomes and analysing data were masked to treatment allocation.
Procedures
In the neoadjuvant phase, patients received oral lapatinib (1500 mg/day), intravenous weekly trastuzumab (4 mg/kg loading dose followed by 2 mg/kg), or a combination of lapatinib (1000 mg/day) plus trastuzumab (same dose as for single agent). After 6 weeks of assigned anti-HER2 therapy, patients were given additional weekly paclitaxel (80 mg/m²) for a further 12 weeks. Defi nitive surgery was done 4 weeks after the last dose of paclitaxel. Chemotherapy was given to all patients within 6 weeks of defi nitive surgery and consisted of three cycles of FEC (fl uorouracil 500 mg/m² plus epirubicin 100 mg/m² plus cyclophosphamide 500 mg/m²) given intravenously every 3 weeks. After chemotherapy, all women received the same anti-HER2 therapy as previously randomly assigned for an additional 34 weeks (52 weeks of anti-HER2 therapy in total). Radiotherapy given concomitantly with anti-HER2 drugs was mandatory in women treated with breast-conserving surgery. Radiotherapy was given according to local guidelines in case of mastectomy, and started 4 weeks after completion of FEC. Endocrine therapy was prescribed for women with hormonereceptor-positive tumours as per local policy, for a minimum duration of 5 years. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0.
Left ventricular ejection fraction was measured with either echocardiography or multiple gate acquisition scan at baseline, at week 6 after randomisation, before surgery, at weeks 1, 13, 25, and 34 of targeted adjuvant therapy, and in the post-treatment follow-up at months 12, 18, 24, 36, 48, and 60, and then yearly up to year 10. A primary cardiac event was defi ned as cardiac death or congestive heart failure, New York Heart Association (NYHA) class III or IV. A secondary cardiac event was defi ned as an asymptomatic (NYHA I) or mildly symptomatic (NYHA II) signifi cant drop in left ventricular ejection fraction, confi rmed by a second left ventricular ejection fraction assessment within roughly 3 weeks. A signifi cant left ventricular ejection fraction drop was defi ned as an absolute decrease of more than ten points below baseline left ventricular ejection fraction, and to below 50%. 
Outcomes
The primary endpoint was pathological complete response, which was reported in 2012. 7 This endpoint was defi ned as the absence of invasive tumour cells in the breast at the time of surgery (ypT0). Secondary endpoints included disease-free and overall survival, safety, and tolerability.
Locoregional pCR was included in the previous report of study fi ndings 7 and defi ned as the absence of invasive tumour cells in the breast and in the axillary lymph nodes at the time of surgery (ypT0/is ypN0). This defi nition was included in protocol amendment 3 (published on May 17, 2013) . This change was introduced to achieve consistency with recommendations from the FDA. 7 Protocol amendment 3 also replaced diseasefree survival with event-free survival to align with recommendations from the FDA. We also modifi ed overall survival to be calculated from randomisation instead of surgery. We implemented these changes in defi nition of survival outcomes (event-free survival and overall survival) after trial completion, but before doing any survival analyses (tests of correlation between pathological complete response and survival outcomes). We did not analyse disease-free or overall survival according to the original protocol specifi cation.
Accordingly, event-free survival was defi ned as the time from randomisation to fi rst event. For women who received surgery for breast cancer, events were defi ned as breast cancer relapse after surgery, second primary malignancy, or death without recurrence. For women who did not have surgery for breast cancer, events were death during clinical follow-up or non-completion of any neoadjuvant investigational product because of disease progression. Overall survival was defi ned as the time from randomisation to death from any cause.
Statistical analysis
The NeoALTTO trial was powered to detect treatment diff erences with respect to the proportion of patients achieving pathological complete response, but was not powered to detect moderate treatment diff erences with respect to event-free or overall survival. Thus, both analyses (event-free and overall survival) are intended to be descriptive. Because the analyses were preplanned, they were to be done even if the number of expected events was low. 10, 11 We did tests of proportionality. All randomly assigned patients were included in the intention-to-treat population.
We examined associations between pathological complete response and event-free or overall survival with landmark analyses. 12, 13 Pathological complete response is a categorising event known after study entry, and therefore analyses of outcome events according to pathological complete response are potentially subject to guarantee time bias, which the landmark analysis controls for. We selected a 30-week landmark time because it would be suffi ciently long for surgery for primary breast cancer to be done, but not too long to eliminate the occurrence of events for assessment of event-free survival. Date of surgery is patient-dependent, and thus not as free of guarantee time bias as the landmark approach that we used in this report.
For event-free and overall survival, the 30-week landmark population included only patients who were still alive and being followed up at 30 weeks after randomisation (appendix). Patients were allocated to two groups according to their pathological complete response status recorded up to week 30 from randomisation, and these groups were compared with respect to event-free and overall survival. We implemented two-sided stratifi ed log-rank tests of event-free and overall survival as Wald tests from the Cox model 14 with pathological complete response status and assigned treatment arm fi tted as covariates and the Other cause 7 (44%) ¶ 5 (31%) 5 (29%)** 10 (48%)** Data are n (%), in which the % refers to the intention-to-treat population, except for reason for discontinuation in which the % refers to patients who did not complete treatment as planned. *Listed as % of patients who discontinued. †Includes three women who withdrew from study. ‡Includes three women who withdrew from investigational product. §Includes two women who withdrew from investigational product. ¶Includes three women who withdrew from investigational product and one woman who withdrew from study. **Includes three women who withdrew from investigational product and two women who withdrew from study.
Table 1: Study drug administration and reasons for discontinuation
See Online for appendix stratifi cation factors entered as strata variables (appendix).
The number of patients with missing pathological complete response status was low, so we excluded these patients from the landmark analysis.
We also did supplemental analyses in which pathological complete response status was included as a timedependent covariate in Cox proportional hazards models (of event-free and overall survival from randomisation) in all patients in the intention-to-treat population whose pathological complete response status was known. These models were adjusted for the assigned treatment group, and the stratifi cation variables.
All analyses of event-free and overall survival were repeated separately for the hormone-receptor-positive and hormone-receptor-negative cohorts. We summarised diff erences in characteristics of these two cohorts using Fisher exact tests.
Incidences and exact 95% CIs 15 were calculated for the primary cardiac endpoint and any cardiac endpoint for each treatment group separately. Incidences in the lapatinib-containing groups were compared with the incidences in the trastuzumab group using unstratifi ed binomial pairwise comparisons. Analyses were done with SAS (version 9.3).
This trial is registered with ClinicalTrials.gov, number NCT00553358.
Role of the funding source
GlaxoSmithKline, the manufacturer of lapatinib, distributed the study drugs and provided fi nancial support to the trial, but imposed no restrictions on study design, data collection, data analysis, data interpretation, or writing of this report. The corresponding author had full access to all data and had fi nal responsibility for the decision to submit for publication.
Results
Of the 455 patients enrolled, 154 (34%) were assigned to the lapatinib group, 149 (33%) to the trastuzumab group, and 152 (33%) to the lapatinib plus trastuzumab group (fi gure 1).
Patients' demographic characteristics, sex, geographical location, and medical history have been previously described. 7 This report presents a pre-specifi ed analysis at 3 years after the last woman had surgery for breast cancer. The median follow-up was 3·77 years (IQR 3·50-4·22) and the median survival follow-up was 3·84 years (3·60-4·24) from randomisation. For these analyses, stratifi cation factors (hormone-receptor status, clinical tumour size, clinical status of lymph nodes, and planned breastconserving surgery) were well balanced across the three treatment groups in the intention-to-treat population (appendix). More participants completed trastuzumab therapy than completed lapatinib therapy in both the single-treatment and combined groups, and in both neoadjuvant and adjuvant phases of the trial (table 1). In the lapatinib and in the combination groups, roughly three-quarters of participants started their assigned treatment for the adjuvant phase (table 1) , and two-thirds completed the adjuvant phase. FEC chemotherapy was completed in 130 (84%) of participants in the lapatinib group, 137 (92%) in the trastuzumab group, and 141 (93%) in the combination group.
38 (25%) of 154 patients in the lapatinib group had an event-free survival event during follow-up, as did 37 (25%) of 149 patients in the trastuzumab group and 30 (20%) of the 152 patients in the combination group (fi gure 1, table 2). Central nervous system was the fi rst site of relapse in 21 (5%) of patients and was equally distributed across the groups (table 2) . 3-year event-free survival was 78% (95% CI 70-84) in the lapatinib group, 76% (68-82) in the trastuzumab group, and 84% (77-89) in the combination group (fi gure 2). Event-free survival did not signifi cantly diff er between those patients in the lapatinib group and the trastuzumab group (HR 1·06, 95% CI 0·66-1·69, p=0·81) nor those in the combination group when compared with trastuzumab alone (0·78, 0·47-1·28, p=0·33). Tests of proportionality of the hazards assumption showed no evidence of non-proportionality for the analysis of event-free survival in comparisons of combination treatment (p=0·70) or lapatinib alone (p=0·62) with trastuzumab alone. There were no signifi cant diff erences between treatment groups when event-free survival was analysed by hormone-receptor status (fi gure 2).
After 3 years of follow-up, 18 (12%) of 154 patients in the lapatinib group had died, as had 23 (15%) of 149 patients in the trastuzumab group, and 13 (9%) of 152 patients in the combination group. 3-year overall survival was 93% (95% CI 87-96) in the lapatinib group, 90% (84-94) in the trastuzumab group, and 95% (90-98) in the combination group. Overall survival did not signifi cantly diff er between patients treated with lapatinib alone and those treated with trastuzumab alone (HR 0·86, 0·45-1·63, p=0·65), nor between those treated with combination therapy and those treated with trastuzumab alone (0·62, 0·30-1·25, p=0·19). There was no signifi cant diff erence between treatment groups when overall survival was analysed by hormone receptor Six patients (one in the lapatinib group, two in the trastuzumab group, and three in the combination group) included in the landmark analysis and classifi ed as not having pathological complete response did not undergo breast cancer surgery, and so were ypTx (unknown). Additionally, one patient (combination group) was shown to have pathological complete response after the landmark date, and was treated as not having achieved pathological complete response in the landmark analysis. Of the 411 patients included in the landmark analysis of event-free survival, 137 (33%) women achieved pathological complete response (table 3) . 3-year event-free survival was signifi cantly better for those women who achieved pathological complete response than for those who did not (HR 0·38, 95% CI 0·22-0·63, p=0·0003; fi gure 3). In preplanned analyses, the hazard ratios for the hormone-receptor-negative cohort (HR 0·34, 95% CI 0·17-0·63, p=0·001) and for the hormone-receptorpositive cohort (0·50, 0·18-1·13, p=0·13) did not signifi cantly diff er (p interaction =0·34). Compared with patients who were hormone-receptor positive, patients who were hormone-receptor negative were more likely to be included in the landmark analysis ( women without pathological complete response). 36 women were excluded from the analysis (two women died before landmark, 20 had survival follow-ups that ended before landmark, and 14 had missing pathological complete response status; table 3). 3-year overall survival was signifi cantly better for women with pathological complete response than for those without pathological complete response (HR 0·35, 95% CI 0·15-0·70, p=0·005; fi gure 3). However, this association was not signifi cant for any individual treatment group (lapatinib group HR 0·41, 95% CI 0·06-1·53, p=0·24; trastuzumab group 0·42, 0·12-1·20, p=0·14; combination group 0·35, 0·07-1·27, p=0·13). In preplanned analyses, the HRs for the hormone-receptor-negative cohort (HR 0·29, 95% CI 0·11-0·62, p=0·003) and the hormone-receptor-positive cohort (0·85, 0·13-3·42, p=0·84) did not signifi cantly diff er (p interaction =0·36).
The time-dependent Cox proportional models for event-free and overall survival showed similar results to those noted in the landmark analyses. The HRs for the time-dependent covariate were 0·37 for event-free survival (95% CI 0·22-0·63, p=0·0002) and 0·34 for overall survival (0·16-0·72, p=0·0046). This fi nding suggests that patients with pathological complete response after neoadjuvant therapy had a reduced risk of subsequent events and death compared with those who did not have pathological complete response.
Adverse events were assessed in 448 women who received at least one dose of study drug. Generally, more adverse events occurred in both groups receiving lapatinib than in the group receiving trastuzumab alone (table 4) . The protocol applied strict defi nitions for hepatic adverse events occurring in those patients receiving lapatinib which lead to permanent lapatinib discontinuation and reporting of serious adverse events in 34 patients receiving lapatinib (either alone or in combination; pCR=pathological complete response. *Excludes six patients (one in the lapatinib group, two in the trastuzumab group, and three in the combination group) who did not undergo surgery and therefore had unknown breast ypT status, and one patient (combination group) with pCR but who had surgery after the landmark date, regarded as not having achieved pCR. protocol amendment (amendment 2, October, 2008) was introduced to reduce the dose of lapatinib to 750 mg daily in the combination group when paclitaxel was added to reduce the incidence of diarrhoea; 54 (36%) of 152 women in the combination group received treatment at reduced dose. The incidence of primary cardiac events remained very low in all three treatment groups (three [<1%] of 448 patients receiving at least one dose of study drug), although there were more primary and secondary cardiac events in the lapatinib plus trastuzumab group (seven [5%]) than in either the lapatinib group (two [1%]) or the trastuzumab group (two [1%]; table 4). Incidence did not signifi cantly diff er between treatment groups for primary cardiac events (combination vs trastuzumab p=0·57; lapatinib vs trastuzumab p=0·32) or any cardiac events (combination vs trastuzumab p=0·09; lapatinib vs trastuzumab p=0·98). No fatal adverse event related to the study drugs was reported in this study.
Discussion
The NeoALTTO trial was not powered to detect signifi cant diff erences in survival outcomes. Our fi ndings showed that women with pathological complete response after neoadjuvant anti-HER2 therapies had signifi cantly better event-free and overall survival than did women without pathological complete response. Women treated with lapatinib plus trastuzumab who achieved pathological complete response had improved 3-year event-free survival, and signifi cantly lower risk of an event, than did those with no pathological complete response, which was not noted for patients receiving lapatinib or trastuzumab alone. To our knowledge, this trial is the fi rst to assess the same assigned anti-HER2 therapy in the adjuvant phase as in the neoadjuvant phase, and the fi rst to show association between pathological complete response and survival outcomes in women treated with a combination of anti-HER2 drugs (panel).
Our results are supported by fi ndings from a metaanalysis of 1989 patients with HER2-positive early breast cancer, showing that patients who achieve pathological complete response after neoadjuvant therapy had a signifi cantly improved event-free and overall survival, irrespective of hormone receptor status. In this group of patients, those with HER2-positive hormone-receptornegative tumours had the greatest benefi t of addition of trastuzumab (event-free survival HR 0·15, 95% CI 0·09-0·27]). 8 Based on these fi ndings, the FDA is able to expedite approval of new treatments in this subset of patients. In our study, women with HER2-positive, hormone-receptor-negative tumours treated with lapatinib plus trastuzumab had the best outcome (3-year event-free survival 86%, 95% CI 75-92).
Other trial fi ndings also show that patients treated with neoadjuvant chemotherapy and trastuzumab with pathological complete response have better survival outcomes than do patients with no pathological complete response. 16, 20, 21 The NOAH trial fi ndings 17 showed that patients treated with neoadjuvant trastuzumab with pathological complete response had a better event-free survival than did those those without pathological complete response after a median follow-up of 5·4 years (HR 0·17, 95% CI 0·08-0·38, p<0·0001).
Importantly, our fi ndings support the notion that in HER2-positive breast cancer, hormone-receptor-positive disease and hormone-receptor-negative disease are two distinct entities. In the landmark analysis, overall and event-free survival was signifi cantly associated with pathological complete response in the hormone-receptornegative cohort but not the hormone-receptor-positive cohort, although the test for interaction was not signifi cant. We previously described that patients with hormone-receptor-negative tumours had higher rates of pathological complete response than did the hormonereceptor-positive cohort. 7 This fi nding has also been shown in other neoadjuvant trials testing the combination of lapatinib plus trastuzumab. 22, 23 Therefore, we believe that new neoadjuvant trials should address these two patient populations separately.
In the metastatic setting, the combination of lapatinib and trastuzumab (without chemotherapy) has been shown to improve progression-free and overall survival compared with lapatinib alone (HR 0·74 [95% CI 0·58-0·94] for progression-free survival and 0·74 [0·57-0·97] for overall survival). 24 Therefore, the dual anti-HER2 inhibition has Adverse events are for the entire trial period, and include those previously reported. No grade 5 toxicities occurred in this trial. *Includes four women (two in the trastuzumab group and two in the lapatinib group) with possible Hy's law criteria (drug-related concomitant elevation of alanine aminotransferase or aspartate aminotransferase greater than three times upper limit of normal and total bilirubin greater than two times the upper limit of normal). †Neutropenia adverse events not occurring during FEC administration. FEC=fl uorouracil, epirubicin, and cyclophosphamide. emerged as a possible treatment both in the metastatic and in the neoadjuvant settings. However, fi ndings from the large phase 3 ALTTO trial (NCT00490139), which enrolled 8381 patients with HER2-positive early breast cancer in four groups (trastuzumab, lapatinib, both drugs in sequence, and both drugs in combination), were presented in 2014. 19 At a median follow-up of 4·5 years and with fewer events for analysis of disease-free survival than planned (555 instead of 850), lapatinib plus trastuzumab did not signifi cantly improve disease-free survival compared with trastuzumab alone (HR 0·84, 97·5% CI 0·70-1·02, p=0·048 [p≤0·025 required for statistical signifi cance to adjust for multiple testing]). Of note, the patient population included in ALTTO had a low risk of recurrence (small and node-negative tumours), as documented by the lower-than-anticipated number of events for disease-free survival.
In our study, toxicity was high in both lapatinibcontaining groups, although the types of toxic eff ects were as expected because of lapatinib use (diarrhoea, rash or erythema, and hepatic toxicity). Additionally, more patients had to stop neoadjuvant treatment because of side-eff ects in the lapatinib-containing groups than in the other groups. Importantly, no major cardiac concerns were raised, even when patients were treated with the combination of both anti-HER2 drugs. In case of adjuvant trastuzumab, some data suggest the reversibility of trastuzumab-related cardiotoxicity at 8 years of median follow-up. 25 Nevertheless, longer follow-up data on the combination of lapatinib plus trastuzumab are still required to establish the full risk of cardiotoxicity in this setting. At this time, no tools are available to identify the patients who will benefi t the most from the combination of lapatinib plus trastuzumab in the neoadjuvant setting. We also could not identify any subgroup of patients with increased likelihood of experiencing adverse events. In a previously reported exploratory analysis, 26 early rash (ie, before starting paclitaxel) was independently associated with a higher chance of pathological complete response, mainly in patients older than 50 years (odds ratio [OR] 3·76, 95% CI 1·69-8·34), but not in those aged 50 years or younger (0·92, 0·45-1·88; p interaction =0·01). In this analysis we noted no signifi cant association between pathological complete response and diarrhoea or hepatic adverse events. 26 In terms of the proportion of patients who achieved pathological complete response, investigators of one neoadjuvant trial testing dual HER2 blockade (pertuzumab plus trastuzumab) reported a similar proportion of patients achieving pathological complete response to those in our trial, whereas fi ndings from other trials have shown higher proportions of patients achieving pathological complete response. 27, 28 However, comparison of pathological complete response rates across studies is diffi cult because the defi nitions used can diff er and the type and duration of chemotherapy also varies. For example, in the TRYPHAENA study, 28 patients received all chemotherapy before surgery, and the defi nition of pathological complete response included breast only (ypT0/is) and did not take into account axillary lymph nodes. Lapatinib plus trastuzumab was also tested in the neoadjuvant setting in the NSABP B-41 trial, 23 although fi ndings from that study did not show a signifi cant diff erence in pathological complete response rates between this combination and a single HER2 drug. 23 In summary, our results show that patients with pathological complete response after neoadjuvant anti-HER2 therapies have better survival outcomes than do those without pathological complete response. These fi ndings support the neoadjuvant approach to test new drugs in early breast cancer, allowing rapid assessment of effi cacy, because pathological complete response is a short-term outcome and the number of patients included in neoadjuvant trials is not large. If this approach is shown to be useful, it could expedite development and approval of new treatments in patients with HER2-positive early breast cancer. However, more data is needed in support of this theory. A preplanned effi cacy analysis will be done in 2·5 years.
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Panel: Research in the context
Systematic review
We searched PubMed from Jan 1, 2001, to April 30, 2014, for full reports of randomised clinical trials in patients with HER2-positive early breast cancer treated with neoadjuvant therapy. We used the terms "lapatinib plus trastuzumab" and "early breast cancer". We identifi ed full texts for two randomised studies of patients treated with neoadjuvant lapatinib plus trastuzumab combined with chemotherapy, and one study of these drugs combined with endocrine therapy. [16] [17] [18] The combination of lapatinib plus trastuzumab was also tested in an adjuvant trial presented at the 2014 ASCO conference.
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Interpretation Dual HER2 inhibition with lapatinib plus trastuzumab combined with weekly paclitaxel has previously been shown to increase pathological complete response compared with either agent alone plus chemotherapy. Findings from our study show that patients with pathological complete response after neoadjuvant anti-HER2 therapy have longer event-free and overall survival than do patients without pathological complete response.
